NEW YORK, May 3, 2011 /PRNewswire/ — Reportlinker.com announces
that a new market research report is available in its
catalogue:
Triple Analysis: Leukemia, Pancreatic Cancer and Prostate
Cancer
This triple analysis focuses on cancer drug development
strategies in Leukemia, Pancreatic Cancer and Prostate Cancer. Each
of these three individual parts is evaluated according to
standardized criteria in a five pillar pipeline drug assessment
methodology to compare drug development strategies in oncology.
This makes it easy to find and compare analysis not only within one
single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this
report:
Part I: Leukemia
The leukemia report part comprises defined and up to date
development strategies for 313 leukemia drugs within the portfolio
of 186 investigators, from Ceased to Marketed. This part
extensively analyses their 204 identified drug targets, organized
into 193 drug target strategies, and assesses them in eight
different compound strategies and eight subindications of
leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline:
From Research and Development to Market
Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to
date development strategies for 213 pancreatic cancer drugs within
the portfolio of 137 investigators, from Ceased to Marketed. This
report part extensively an
‘/>”/>
